Učitavanje...

Targeting epigenetics as atherosclerosis treatment: an updated view

This review discusses the current developments on epigenetic inhibition as treatment for atherosclerosis. RECENT FINDINGS: The first phase III clinical trial targeting epigenetics in cardiovascular disease (CVD), BETonMACE, using the bromodomain inhibitor apabetalone (RVX-208) showed no significant...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Curr Opin Lipidol
Glavni autori: Neele, Annette E., Willemsen, Lisa, Chen, Hung-Jen, Dzobo, Kim E., de Winther, Menno P.J.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2020
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7752220/
https://ncbi.nlm.nih.gov/pubmed/33027226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOL.0000000000000711
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!